Uni-Bio Science Group is a leading Chinese biopharmaceutical healthcare company engaged in the research, development, production and commercialisation of biopharmaceuticals for the Chinese healthcare market. The Company is headquartered in Hong Kong and is listed on the main board of the Stock Exchange of Hong Kong Limited (HKEx stock code: 0690). Uni-Bio Science has developed a strong competitive portfolio of market-leading products in diabetes, ophthalmology and dermatology across China. Our products are manufactured at our state-of-the-art cGMP certified plants in Beijing and Shenzhen.
The Company is also committed to developing next-generation innovative therapies and having a growing pipeline of drug candidates that, with “blockbuster” potential, are complementary to its existing portfolio.
Uni-Bio Science is a leading Chinese biopharmaceutical healthcare company engaged in the research, development, production and commercialisation of biopharmaceuticals for the Chinese healthcare market. We are committed to the research and development, commercialisation and manufacturing of innovative drugs to address the unmet medical needs in China. We currently manufacture and commercialise four marketed drugs:
1. GeneTime® (recombinant human epidermal growth factor liquid for external use), a dermatology drug, mainly used for burns and wound healing, and is one of the leading products in the China. The drug is on the national reimbursement drug list (NRDL).
2. GeneSoft® (recombinant human epidermal growth factor derivative eye drops), an ophthalmology drug, mainly used for ophthalmic surgeries and ophthalmic wound healing. We are in the process of applying for NRDL listing.
3. Pinup® (Voriconazole), an anti-infective drug, mainly used for treating fungal infection, which is also a national reimbursement drug.
4. Mitiglinide, a best-in-class prescription oral drug for the treatment of type 2 diabetes, by lowering blood glucose content. The drug was recently included into the 2017 NRDL.
GeneTime® and GeneSoft® are both biologics manufactured by Shenzhen Watsin, while Pinup® is a chemical drug manufactured by Beijing Genetech.
Additionally, Uni-Bio Science has a growing pipeline of drug candidates that, with “blockbuster” potential, are complementary to, and have strong synergy with its existing portfolio of marketed therapies.
One of the Company’s lead programmes in currently in development includes Uni-PTH (Recombinant Human Parathyroid Hormone 1-34: for the treatment of osteoporosis and Uni-E4 - a next-generation drug for the treatment of Type 2 diabetes. Uni-PTH is the only drug class which has been shown to increase bone mass density, reduce bone fracture, and effectively manage ostealgia (bone pain). It has completed phase III clinical trials, and its New Drug Application was accepted by the China Food and Drug Administration (CFDA) in Nov 2017.
In clinical studies, Uni-E4, another one of Uni-Bio's leading programmes has been shown to be an effective treatment for Type-2 diabetes, with the added benefit of relieving obesity in overweight patients, lowering the risk of hypoglycemia and promoting β-cell regeneration. It has completed phase III clinical trials and Uni-Bio Science continued to develop the next-genercation of the product- liquid formulation.
Given the large number of patients suffering from osteoporosis and diabetes in China, the Company has full confidence in the potential of these two new drugs.
According to the Stock Exchange Industry Classification System, the Company belongs to pharmaceutical sector under Health & Personal Care. Under Wind’s classification, the Company belongs to the biotechnology sector.
As of the 30th of June 2018, approximately 24.8% of Uni-Bio Science’s shares are held by Mr. Kingsley LEUNG, Chairman of the board; 14.8% of which is registered in the name of Lord Profit Limited, a company that is wholly owned by him, while the remaining around 10% is registered under the name of Automatic Result Limited, which is wholly owned my MJKPC Holdings Limited, a family trust of which Mr. Kingsley LEUNG is one of the discretionary objects. Mr. David CHEN, Vice Chairman, holds approximately 6.4% of shares. Meanwhile, Heungkong Great Health GP Limited and Overseas Capital Assets Limited own approximately 17.67% and 10.63% of shares respectively as strategic investors. The remaining shares of the Company, are held by institutional and retail investors.
Overseas Capital Assets Limited is an investment company. Its stake in Uni-Bio Science is categorized as financial investment and is not involved in the daily operations of our business.
